Tracey McCain
Vermögen: 742 391 $ am 31.05.2026
Vermögen: 742 391 $ am 31.05.2026
Tracey L.
McCain is currently an Independent Director at Kiniksa Pharmaceuticals Ltd. since 2018, an Independent Director at Kiniksa Pharmaceuticals International Plc since 2024, and a Trustee at Dana-Farber Cancer Institute, Inc. Former roles include Independent Director at ImmunoGen, Inc. from 2021 to 2024, Secretary, Chief Legal & Compliance Officer at Blueprint Medicines Corp.
from 2016 to 2025, Senior Vice President & Head-Legal at Genzyme Therapeutics Ltd. in 2016, General Counsel at Genzyme Corp.
from 1997 to 2016, and Associate at Palmer & Dodge LLP.
Education includes an undergraduate degree from the University of Pennsylvania in 1989 and a graduate degree from Columbia Law School in 1992.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0.03% | 29.05.2026 | 15’345 ( 0.03% ) | 742 391 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Direktor/Vorstandsmitglied | 01.02.2018 |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Compliance Officer | 01.10.2025 |
| IMMUNOGEN, INC. | Direktor/Vorstandsmitglied | 12.02.2024 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | General Counsel | 02.09.2016 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | General Counsel | 01.09.2016 |
Palmer & Dodge LLP
Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Health Services |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Palmer & Dodge LLP
Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Columbia Law School
Columbia Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen